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Abstract: Background: the International Cohort Consortium of Infectious Disease (RESPOND) is a
collaboration dedicated to research on HIV and other infectious diseases. Methods: RESPOND is a
flexible organization, with several independent substudies operating under one shared governance.
HIV-related variables, including full antiretroviral therapy (ART) history, are collected annually for
all participants and merged with substudy specific data into a shared data pool. Incident clinical
events are reported using standardized forms. Prospective follow-up started 1/10/17 (enrolment)
with retrospective data collected back to 01/01/12. Results: Overall, 17 cohorts from Europe and
Australia provided data on 26,258 people living with HIV (PLWH). The majority (43.3%) of the
population were white, with men-sex-with-men accounting for 43.3% of the risk for HIV acquisition.
The median age was 48 years (IQR 40–56) and 5.2% and 25.5% were known to be co-infected with
hepatitis B or C. While 5.3% were ART-naïve, the median duration on ART was 10.1 years (4.8–17.6),
with 89.5% having a VL &lt;200 copies/mL and the median CD4 count being 621 cells/µL (438–830).
Malignancies (n = 361) and cardiovascular disease (n = 168) were the predominant reported clinical
events. Conclusion: RESPOND’s large, diverse study population and standardized clinical endpoints
puts the consortium in a unique position to respond to the diverse modern challenges for PLWH.
Keywords: HIV; cohort; observational study; hepatitis; public health; tuberculosis; pharmacovigilance
1. Introduction
The International Cohort Consortium of Infectious Disease (RESPOND) was formed in 2017 as a
prospective, multi-cohort collaboration for the study of infectious diseases, with a special focus on
people living with HIV (PLWH). RESPOND was founded upon the groundwork laid by outstanding
European HIV cohort collaborations such as EuroSIDA, the Collaboration of Observational HIV
Epidemiological Research Europe (COHERE), and Data Collection on Adverse events of Anti-HIV
Drugs (D:A:D) studies, and utilizes a similar, well-established infrastructure [1–4].
RESPOND offers a research framework with a flexible organization, applying a common data
model across different substudies, utilizing one shared data pool. Additionally, all involved in
RESPOND can contribute to the ongoing scientific agendas. Together, these dynamic features facilitate
responses to a broad range of unmet research needs.
The large size of RESPOND allows scientific questions to be addressed that individual cohorts do
not have the size to investigate themselves. Furthermore, the heterogeneous study population with
participants from across the whole of Europe and Australia and a high degree of data quality—including
the central validation of standardized clinical event definitions—ensure that the results are reliable
and applicable to a broader population of PLWH. RESPOND will address clinically relevant research
questions, such as the risk and outcomes of non-AIDS comorbidities and the possible relationship to
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long-term ART exposure; to the outcomes and treatment of viral hepatitis B (HBV), hepatitis C (HCV),
and tuberculosis (TB) co-infections; and to support public health initiatives.
In this cohort profile, we will detail RESPOND’s organization, substudies, data collection and
quality assurances, baseline characteristics, scientific findings to date, and focus areas going forward.
2. Materials and Methods:
2.1. Cohort Participation
The cohorts that constitute RESPOND are largely collaborators from the EuroSIDA-, COHERE-,
and D:A:D multi-cohort studies. However, the consortium is an open network that welcomes additional
cohorts to join if predefined criteria regarding the inclusion of a minimum number of participants,
the need for a designated data manager, and data quantity- and quality are met. The first (and current)
version of these criteria can be found in full at https://chip.dk/Studies/RESPOND/Study-documents [5].
2.2. Inclusion Criteria
PLWH older than 18 years were eligible for inclusion. Each cohort contributed a pre-defined
minimum number of participants related to the size of the specific cohort, according to agreed inclusion
and exclusion criteria carefully designed to include a representative population. As RESPOND focuses
on contemporary outcomes in PLWH, only individuals under prospective follow-up after 2011 were
included. Two groups of individuals were enrolled; the first group started an integrase strand transfer
inhibitor (INSTI) after 1/1/2012, with the baseline defined as the date of starting the INSTI. The second
group did not start an INSTI at enrolment and had baseline defined as the latest of 1/1/2012 or enrolment
into the local cohort. The participants from both groups were required to have a CD4 count and HIV
viral load (VL) measurement in the 12 months prior to or within 3 months after baseline (Figure 1) [6].
To minimize the risks of selection and survival bias to the greatest extent possible, individuals
who had died or had been lost to follow up in the period 1/1/2012–1/10/2017 were enrolled for the
initial merger (more details in Section 2.6 on data collection and quality assurance).
2.3. Ethical Considerations
Studies performed within the RESPOND consortium are conducted according to the Declaration of
Helsinki [7] and the requirements of Good Clinical Practice (GCP), as defined in the European Union’s (EU)
GCP Directive [8]. All the data supplied to RESPOND follow local or national guidelines as appropriate,
and enrolled participants are pseudonymized by the assignment of a unique identifier by the participating
cohort before data transfer. As data controller, the Coordinating Centre (CC) located within the Danish
Capital Region of Copenhagen, Denmark, stores, shares, and protects data in accordance with current
legislation and under approval by The Danish Data Protection Agency (j.nr.: RH-2018-15, 26/1/2018),
currently under the EU’s General Data Protection Regulation (EU) 2016/679.
RESPOND is registered at Clinicaltrial.gov (identifier: NCT04090151, 16/9/2019).
2.4. Consortium Organization and Governance:
The consortium is overseen by an Executive Committee (EC), which is composed of scientific
stakeholders, representatives from the three largest participating cohorts, and the chairs from Scientific
Steering Committee (SSC) (Figure 2). The role of the EC is to ensure the financial and structural integrity
of RESPOND and to safeguard that study objectives are being met in a timely manner. However,
the EC has no direct involvement in formulating specific scientific agendas, which is carried out
under the supervision of the SSC [6]. The principal investigators from all the participating cohorts;
HIV community representatives; research moderators; and scientific stakeholders, recruited based on
their academic credentials, form the RESPOND SSC [6].
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and exclusion criteria.
The scientific agendas that drive the consortium’s scientific progression are formed under several
substudies termed scientific interest groups (SIGs; Figure 2). These substudies utilize the common
RESPOND data pool and have the option to collect additional substudy specific data. This flexible and
open structure enables new substudies to easy be added to the consortium’s on-going operations if
imminent research questions arise. Participation in the SIGs is open for all individuals associated with
RESPOND cohor s, community, funders, and extern l expe ts.
The RESPOND SIGs are form d and managed by two scientific moderators tha are responsible
for organizing all scientific activities within the SIG and for ensuring a contemporary research agenda.
Relevant variables for SIG analyses may or may not already be collected as part of the standard
RESPOND data collection. If a collection of new variables is needed, funds for the collection of these
and following analysis must first be obtained, and this relies on the SIG participants and moderators.
Therefore, the time from conceptualizing to a functioning SIG largely depends on the SIG’s scientific
focus and the availability of data. More information on the initiation of a SIG in RESPOND can
be obtained via the RESPOND webpage (https://chip.dk/Studies/RESPOND) or by contacting the
RESPOND secretariat (respond.rigshospitalet@regionh.dk).
Secretariat functions and data management are handled by the Coordinating Centre (CC).
The statistical centers located at University College Londo , England, a d Kirby Institute Sydney,
Au tr lia, manage ata cleaning, statistical analyses, and support for cohort-led specific analyses.
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Figure 2. Organization of RESPOND. The executive committee oversee the overall financial wellbeing
and scientific progression, while the scientific steering committee supervises the scientific integrity
and research conducted. Research agendas are developed in the sub studies/scientific interest groups:
Public Health, Outcomes with Antiretroviral Treatment, Hepatitis and Tuberculosis (the latter under
development). Each SIG may have multiple underlying working groups (WG) dedicated to developing
specific subtopics. All the participating cohorts supply core RESPOND data to the data pool. In addition,
study-specific data can be collected by a subset of cohorts involved in specific SIGs which are also
merged into the data pool. All the data can be utilized by the different SIGs upon permission from
the cohorts.
2.5. Scientific Focus and Development of Scientific Agendas
At present, there are three operational SIGs: The Clinical Outcomes of Antiretroviral Treatment
(Outcomes) SIG, the Hepatitis SIG, and the Public Health SIG. A TB SIG is under formation (Figure 2).
The Outcomes SIG investigates the incidence of, risk factors for, and outcomes related to non-AIDS
comorbidities and the use of individual antiretroviral agents (ARVs). The Hepatitis SIG explores
specific questions relevant for PLWH co-infected with HBV (with or without hepatitis D virus) and
HCV. The purpose of the Public Health SIG is to implement studies of broader public health relevance
using cohort clinical data in collaboration with EU surveillance institutions such as the European
Center for Disease Control (ECDC), the World Health Organization (WHO), and other European-wide
public health projects.
All the members of a SIG may propose scientific projects [9]. Two appointed moderators of the
SIG will initially assess the overall relevance and feasibility, before the proposal is further discussed
and developed within the wider SIG. Smaller working groups can be formed by SIG members with a
special interest within the spectrum of an SIG’s research, taking advantage of the interest and expertise
of other working group members (Figure 2).
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2.6. Data Collection and Quality Assurance
The first data merger for RESPOND took place in 2017, collecting data for the period
01/01/12–01/10/2017. Since then, prospectively collected data from cohorts are annually submitted to
the RESPOND CC and merged with the RESPOND data pool.
The clinical and demographic variables collected by RESPOND are summarized in Table 1. All the
variables are categorized as either RESPOND core variables—which all participating cohorts are
required to supply for all enrolled participants—or study-specific variables, which are only required
for participants in specific substudies. Both types of variable are merged into the common data pool
and can be included in all RESPOND substudies (Figure 2). Data can only be utilized upon approval by
the individual cohorts that supplied the data, and participation in specific substudies can be retracted
at any time, following the RESPOND governance [6].
RESPOND collects and stores data in the HIV Cohorts Data Exchange Protocol (HICDEP)
format [10], detailed in the RESPOND Standard Operating Procedure [11]. Data is transferred to
the RESPOND CC in one of two ways: by manually entering data via the secure, browser-based
real-time Research Electronic Data Capture platform (REDCap) [12]; or by transferring larger amounts
of data on designated templates, using the in-house developed RESPOND Electronic Submission Tool
(REST). Both systems are operated from a secure location, managed by the Danish Capital Regions IT
Department, and use secure communication (https), with only authorized personnel having access to
the systems [13]. The submission of routine follow-up data occurs annually in the period between the
1st of October to the 1st of December.
Both REST and REDCap users will be met with multiple automated quality assurance checks
when uploading or entering data. These built-in checks enable sites and cohorts to correct errors before
data submission. Within a week of submission, raw datasets from individual cohorts are assessed for
completeness and correctness by staff at the RESPOND CC. The cohorts are queried and asked to clarify
and immediately resubmit corrected data as appropriate. After data cleaning, the statistical center
produces comprehensive summaries of the data quality and completeness and provides individual
feedback to cohorts, with the intent of improving data prior to the next data submission. In brief,
assessments are made for all specific core variable since the last data submission. Correctness is
assessed by a wide range of checks, aimed at identifying unintuitive reporting or systematic import
errors (i.e., codes indicating a participant is receiving ≥2 INSTIs simultaneously, a participant who
has no available HIV-RNA measurement available within the proximity of a change in ART, or a
participant with no new serum creatinin measure).
Information on clinical events is collected using non-identifiable data on study-specific Case Report
Forms (CRFs) for the following events: myocardial infarction (MI), stroke, invasive cardiovascular
procedure (ICP; coronary angioplasties/stenting, coronary by-pass surgery, and carotid endarterectomy),
end-stage liver and renal disease (ESLD and ESRD), and AIDS- and non-AIDS defining malignancy
(ADM and NADM; excluding non-melanoma skin cancers and pre-cancers). Opposite from the routine
follow-up data, CRFs are collected in real time from the period the 1st of December to the 1st of July.
After CRFs are received at the CC, events are validated by a specially trained medical doctor following
a prespecified algorithm [14], which mirrors the event definitions developed in the D:A:D study.
To further increase the data quality, a proportion of all the validated events are reviewed by an external
expert from the relevant medical specialty (i.e., MI events are reviewed by an external independent
senior cardiologist). CRFs with causes of death (CoDe) must be submitted for all deceased participants,
and the cause of death is coded by a trained medical doctor following the CoDe protocol [15].
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Table 1. Overview of the RESPOND core variables collected by all the participating cohorts, and study-specific variables collected as part of the RESPOND substudies.
RESPOND Core Variables Study Specific Variables
Date of birth Ethnicity
Sex Country of origin
Date first seen at department Non-intravenous illicit drug use
Date of first positive HIV1-Ab/Ag test Intravenous drug use
Height
Weigth
Baseline smoking status
Current smoking status
Risk of HIV acquisition of infection
Risk of HCV acquisition of infection
Demographics and Basic Information
Risk of HBV acquisition of infection
Infection Related Laboratory Values
HIV RNA CD8 counts
CD4 counts HLA B*57:01
HCV-antibodies HCV genotype (and subtype)
HCV RNA Blood samples
HBS Antigen Tuberculosis diagnosis
HBV DNA Tuberculosis resistance
Creatinin ALT
Total cholesterol AST
HDL cholesterol INR
LDL cholesterol Hemoglobin
Triglycerides Bilirubin
HbA1C or blood glucose Albumin
Laboratory Values
Urine dipstick tests for proteinuria
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Table 1. Cont.
RESPOND Core Variables Study Specific Variables
Antiviral Treatment Treatment *
Nucleos(t)ide reverse transcriptase inhibitors Hepatitis C treatment
Non-nucleotide reverse transcriptase inhibitors
Protease inhibitors (cobicistat/ritonavir boosted or upboosted)
Integrase strand transfer inhibitors Entry inhibitors
Fusion inhibitors
Anti-thrombotic drugs Opioid substitution therapy
Anti-hypertensive drugs Anti-Tuberculosis treatment
Anti-diabetic drugsNon-Antiviral Treatment Treatment *
Lipid lowering drugs
Other Paraclinical Data
Blood pressure Bone Mass density: t-score
Bone Mass density: z-score
Bone Mass density area
Liver trans elastography (fibroscan)
Liver biopsy (metavir stage)
Acoustic radiation force impulse (ARFI)
HCC screening (Abdominal CT/MRI
and ultrasound)
Myocardial Infarctions ** Pregnancy
Stroke **
Invasive cardiovascular procedures (coronary
angioplasty/stenting, coronary bypass surgery, and carotid
endarterectomi) **
Non-AIDS defining malignancies **
End-stage liver disease **
End-stage renal disease **
Fracture **
AIDS events (including AIDS defining cancers **)
Clinical Events
Deaths ***
*: Including start and stop dates and reasons discontinuations. **: A designated CRF must be filled out for events occurring after baseline. ***: A designated CRF for cause of death must be
filled out for deaths occurring after baseline.
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Substantial quality assurance steps are in place to limit the potential underreporting of clinical
events, including the assessment of the incidence rates of events reported from all individual cohorts.
Likewise, the proportions of queried and dismissed events are continuously monitored to identify
areas where individual cohorts may need to focus their attention and increase the amount and quality
of collected data. Further, if a CRF does not contain the adequate information to allow for central
validation, the cohorts are queried up to three times.
3. Results
3.1. Baseline Demographics and Clinical Caracteristics
By 1/10/17, 17 cohorts had agreed to engage in the consortium; 15 cohorts contributed to the first
data merger, with a total of 26,258 individuals (Table 2). Two additional cohorts subsequently joined
the second data merger in 2018. After the third data merger in 2019, RESPOND followed more than
34,000 PLWH.
At the study enrollment, the median age was 48 years (interquartile range, IQR, 40–56); 24.9%
were younger than 40 years and 14.6% were older than 60 years. Women (25.7%) and persons of
non-white ethnicity (27.6%) made up a substantial proportion of the study population. The RESPOND
participants originated mainly from Western- (51.2%) and Southern Europe (26.6%), with 12.5% from
Central Eastern- or Eastern Europe and 9.7% from Northern Europe (including Australia). Heterosexual
contact and injecting drug use, respectively, accounted for 34.3% and 14.9% of the risk factors for
HIV acquisition, with men-who-have-sex-with-men (MSM) being the largest group (43.4%). Hepatitis
B- or C co-infection were seen in 5.2% and 25.5% of the participants. At the time of enrollment into
RESPOND, the majority (89.5%) of participants had a VL <200 copies/mL and 67.0% had a CD4
count >500 cells/µL. The nadir CD4 count was ≤50 cells/µL for 16.4%. The median baseline date was
06/17 [12/15–09/17].
3.2. ART Exposure
While 5.3% were ART-naïve at enrollment, the median duration of ART was 10.1 years (4.8–17.6),
(Figure 3a). Dolutegravir (DTG) was the INSTI with the greatest cumulative exposure time, followed
by raltegravir (RAL) and cobicistat boosted elvitegravir (EVG/c) (7835, 6044, and 3100 person-years of
follow-up (PYFU), respectively). For contemporary boosted protease inhibitors (PI/b), the duration of
exposure to darunavir (DRV/b) and atazanavir (ATV/b) was relatively similar (21,400 and 23,060 PYFU).
For non-nucleoside reverse transcriptase inhibitors (NNRTIs), the exposure time to efavirenz (EFV)
was much higher than that to rilpivirine (RPV; 7521 and 54,236 PYFU). In descending order, the highest
cumulative exposures for nucleot(s)ide-analogue reverse transcriptase inhibitors were seen for
lamivudine (3TC; 119,388 PYFU), tenofovir disoproxil fumarate (TDF; 102,459 PYFU), emtricitabine
(FTC; 83,613 PYFU), abacavir (ABC; 54,314 PYFU), and tenofovir alafenamide (TAF; 3294 PYFU).
3.3. Clinical Events
At time of the first data merger, the CC had received and centrally validated >90% of all expected
event forms, with a total of 716 events. The predominant events were malignancies (n = 351 (50.4%),
of which 35.9% were NADM and 14.5% were ADM; Figure 3b), followed by CVD (168 (23.5%), of which
9.4% were ICP, 7.4% were MI, and 6.7% stroke), fractures (131, 18.0%), ESLD (45, 6.0%), and ESRD
(11, 2.0%). In addition, there were 942 deaths recorded in the period between 1/1/12 and 1/10/17.
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Table 2. Characteristics at the baseline after first data merger.
n %
All 26,258 100
Age (Years)
≤40 6488 24.9
41–50 7909 30.4
51–60 7811 30.0
>60 3810 14.6
Southern Europe (plus Argentina) 6933 26.6
Western Europe 13,320 51.2
Northern Europe (plus Australia) 2524 9.7
Central Eastern Europe 1421 5.5
Region
Eastern Europe 1820 7.0
Sex
Male 19,329 74.3
Female 6679 25.7
White 18,834 72.4
Black 4368 16.8Race
Other/Unknown 2816 10.8
HIV Acquisition Risk
Men-sex-with-men 11,300 43.4
Intraveneous drug use 3883 14.9
Heterosexual 8931 34.3
Other/Unknown 1904 7.3
<200 24,073 89.5
≥200 2185 10.5Viral load (copies/mL) *
<LOD, where LOD> 200 cp/mL ** 165 0.6
ART naïve
No 24,634 94.7
Yes 1384 5.3
≤200 1410 5.4
201–350 2689 10.3
351–500 4429 17.0
501–750 8758 33.7
CD4 (cells/µL) ***
>750 8861 33.3
CD4 Nadir (cells/µL)
≤50 4268 16.4
51–200 8233 31.6
201–350 7813 30.0
>350 5544 21.3
≤2011 20,723 79.6
>2012 4494 17.3Date of HIV diagnosis
Unknown 801 3.1
HBV status
Negative 21,088 81.1
Positive 1347 5.2
Unknown 3583 13.8
Negative 16,727 64.3
Positive 6622 25.5HCV status
Unknown 2669 10.3
Median Interquartile Range
Age (years) 48 40–56
CD4 (cells/µL) 621 438–830
CD4 Nadir (cells/µL) 208 91–327
Baseline date
(month/year) 6/17 12/15–9/17
* Viral load (VL) was unknown for 16 participants at the first data merger. ** LOD: Lower limit of detection.
LOD was >200 copies/mL for the specific assay used for the participants’ latest measurement, with the results being
a VL < than the specific LOD. *** CD4 was unknown for 71 participants at the first data merger.
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3.4. i t ESPOND Findings
first analyses performed within the Outcomes SIG hav focused on INSTI-based ART.
Greenberg et al. [15] examined the uptake and discontinuation of RAL, EVG/c, and DTG among 9702
RESPOND participants. At 6 months after initiation, 9% had discontinued their INSTI treatment,
with the main reason being related to drug toxicity (5%). Nervous system-related toxicities accounted
for the highest proportion of toxicity-related discontinuations for DTG. The overall conclusion from
the large and geographically diverse study setting was that even though specific adverse effects may
be overrepresented for individual drugs, INSTIs were generally well tolerated by most participants.
In a second analysis by Neesgaard et al. [16], the virologic nd immu ologic outcomes of treatment
with INSTI ere compared to the u e of contemporary PI/b and NNRTIs in 13,703 participants, with a
focus on subgroups stratified by ART experience and viremia at baseline. Using both composite
treatment outcome and on-treatment analysis, the 12 months durability and efficacy were evaluated.
INSTI- and NNRTI-based regimens were consistently found to be more durable and efficacious than
PI/b-based regimens. As a follow-up study, Mocroft et al. [17] explored possible differences in the
virologic and immunologic outcomes for the subset of ART-naïves, depending on the age group
(≤40, 40–50, and >50 years), CD4 count (≤350 versus >350 cells /mm3), or VL at ART initiation
(≤100,000 versus >100,000 copies/mL), without finding strong evidence that the differences in treatment
response wer ifferent in the key subgroups.
RESPOND have also focused analyses on the c temporary question of ART strategies with two
(2DR) or three drug (3DR) combinations. Greenberg et al. [18] c mpared the occurrence of severe
clinical events among 1088 participants on 2DR to 8703 on 3DR. Persons on 2DRs tended to be older
and have more comorbidities than those on 3DRs, and after accounting for these characteristics there
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was a similar short-term incidence of severe clinical events for those on 2DRs compared to those
on 3DRs.
The Public Health SIG recently presented proof of concept data from a method of using data from
a random sample of patients to estimate a clinic’s percentage of individuals virologically suppressed
on ART to construct the right-hand side of the continuum of care in settings with fragmented data to
support surveillance as well as quality control [19].
4. Discussion
RESPOND is a large multicenter cohort consortium with the participation of 17 large, pre-existing
cohorts from across Europe and Australia. At present (2020), more than 34,000 PLWH have been enrolled.
Building on the sound scientific collaborations ongoing for more than three decades in the EuroSIDA,
COHERE, and D:A:D multicohort studies, RESPOND represents a flexible yet well-structured
framework for addressing unmet scientific questions for HIV and other infectious diseases.
4.1. Pharmacovigilance and Comorbidities in a Modern Era
The development of well-tolerated, effective ART is one of the great milestones in modern medical
history, having transformed HIV from a deadly progressive infection into a chronic condition for
those with access to care [20]. However, lifelong treatment comes with a potential risk of cumulative
long-term toxicities—and with the increased life expectancy [21], age-related comorbidities have
become increasingly prevalent in PLWH [22–25]. Consequently, PLWH now need multi-disciplinary
management, including the assessment of polypharmacy, potential drug-drug interactions, and the
screening and management of comorbidities and co-infections.
Due to the large size, substantial heterogeneity, extended follow-up time, and systematic collection
of centrally validated endpoints, RESPOND is in a unique position to conduct well-powered
pharmacovigilance studies and to assess the impact of demographics, traditional risk factors,
HIV-related factors, and ART on a wide range of comorbidities. RESPOND will systematically
assess the safety of newer ARVs, with a particular focus on INSTIs and other ARVs that may still be
used in only a subset of PLWH and that therefore require a large dataset to reliably assess the longer
term outcomes. Furthermore, the large number of persons under follow-up will allow RESPOND to
focus on well-defined clinical endpoints, where individual cohorts may have too limited statistical
power to conduct reliable analyses. In addition, the large and diverse composition of the consortium
population provides the possibility of subgroup analyses stratified by clinical characteristics such
as sex, smoking status, and age, in addition to stratifications based on geographical- and economic
regions. Thus, the results will be broadly generalizable to the population of PLWH seen in routine
clinical care in across Europe and Australia.
Going forward, RESPOND will help generate pivotal information necessary for tailoring ART to
meet the individual needs of an aging population of PLWH and to gain insights into the development
and outcomes of comorbidities.
The RESPOND data pool already holds a significant amount of data on ARV exposures,
comorbidities, and mortality, with the most common clinical events being CVD and malignancies.
Therefore, RESPOND will focus on these clinical events in the shorter term. More specifically, analysis
investigating the possible associations between cumulative INSTI exposure and the risk of CVD and
malignancies are ongoing. Other analyses will investigate weight gain and dyslipidemia in PLWH
using contemporary ART and causes of death in PLWH within RESPOND. Additional follow-up time
will allow the analysis of other less frequently occurring comorbidities and the possible relation to the
use and discontinuation of modern ART.
4.2. Hepatitis and Other Infectious Diseases
While HIV is the main focus area of RESPOND for the immediate future, there is a significant
amount of research activity revolving around other co-infections within the consortium. Founded in
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the EuroSIDA cohort study network, the Hepatitis SIG has now been incorporated into the consortium
and has recently added HCV treatment data and HBV-DNA to the already collected information on
HCV-RNA and hepatitis serology. Among the ongoing research areas are the long-term outcomes of
direct acting antivirals, HCV reinfection rates, and HBV/HDV co-infections. In addition, plans are
being made to identify biomarkers predicting the development of hepatocellular carcinoma and
investigations on the impact of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
in PLWH.
TB is a leading cause of infection-related deaths worldwide [26], with high incidences in
Sub-Saharan Africa, Asia, and Eastern Europe. It is also the most prevalent AIDS-defining disease and
is overrepresented among PLWH [27]. Although TB was not part of the initial focus of RESPOND,
the TB:HIV network [28] has now established links within RESPOND with the consortium’s dynamic
framework, enabling the formation of a TB-focused substudy and the inclusion of basic TB-related
variables into the latest RESPOND data collection. The SIG plans to examine the risk factors for
TB, the use of newer antimycobacterial treatments, and the frequency of multiresistant TB strains,
generating valuable knowledge about HIV/TB coinfections from a real-life perspective.
While these substudies do not provide an exhaustive list of co-infections for the population of
PLWH, they show the ability of RESPOND to incorporate the standardized data collection of newly
proposed data items across the network. As such, there is no limitation on which substudies can
be undertaken within the consortium if there is a strong academic driving force and research need
behind it.
4.3. Using Cohort Data to Support Public Health Challenges
The public health SIG was created to support the use of HIV cohort data to address public health
challenges. Collaboration between national surveillance institutions and clinical cohorts can help
address gaps in data availability; however, many countries have poor cross-communication or lack
those channels for data sharing.
To reach the ambition of the 90-90-90 goals launched by the United Nations program on HIV/AIDS
in 2014 [29], reliable estimates are needed on the size and the spread of the infection, the proportion on
ART, and how many of those have viral suppression. Having provided proof of concept for using a
smaller sample size to estimate the proportion of PLWH on ART and with viral suppression, the Public
Health SIG will move on to conceptualize the method in an online tool. Subsequent studies will seek
to validate this tool. The methodology could also play a role in assessing the TB and HCV disease
burdens and treatment programs in locations where surveillance data is currently lacking.
The linked pilot PrEP and Resistance project (PrEPaRE; separate ethic approval: H-19043630,
13 November 2019) [30], which is also part of the Public Health SIG’s agenda, will investigate the
frequency of prior PrEP use in individuals newly diagnosed with HIV. The project has initiated
collaborations with more than 70 centers and, depending on the feasibility of reaching the enrollment
numbers, follow-up studies will assess possible resistance patterns and correlate these to the drugs
taken as part of PrEP.
The ability to quickly utilize the network within and around RESPOND is in part possible due to
RESPOND’s widely used HICDEP-based data collection. This model also facilitates partnerships with
other collaborations, as exemplified by the European Union’s horizon 2020 project Common Action
Against HIV/TB/HCV Across the Regions of Europe (CARE) [31], where branches of CARE quickly
adopted the RESPOND model to rapidly transfer local data on more than 4000 participants into one
common data repository.
4.4. Limitations
As RESPOND is a non-randomized observational collaboration, the inherent limitations of possible
missing data, selection bias, and unmeasured confounding apply for all analyses. To address the
data quality and completeness, RESPOND employs a comprehensive and rigorous quality assurance
Microorganisms 2020, 8, 1164 13 of 16
system consisting of both automated and manual checks to ensure a high degree of data completeness
and quality. In addition, the size of the study makes it possible to adjust for a wide range of
possible confounding factors and perform adequately powered interaction and/or subgroup analyses.
In addition, RESPOND will explore modern statistical methods such as causal inference, bioinformatics,
and artificial intelligence.
At present RESPOND does not systematically collect data on resistance or HIV-subtype—both of
which are subject to considerable heterogeneity in our study population [32,33], nor does the study
collect data on use of therapeutics that have not yet been approved by the European Medicines Agency.
As the participating cohorts are based in Europe or Australia, the conclusion from RESPOND
studies may not necessarily extend to PLWH from countries outside these regions and from
resource-limited settings. Additionally, RESPOND includes only individuals from HIV cohorts
able to comply with the RESPOND data collection principles and requirements.
5. Conclusions
In conclusion, RESPOND is a newly formed, flexible, and open consortium based on a
well-established infrastructure and dedicated to research related to HIV and other infectious diseases.
RESPOND has a geographically diverse study population; has a large data pool containing key
HIV-related and study-specific information; employs a rigorous data quality program; and includes a
collection of standardized, centrally validated clinical outcomes. These qualities place the consortium
in a unique position to respond to a wide range of modern challenges for PLWH.
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